Iloprost Waymade (Iloprost)

Iloprost is a synthetic analogue of prostacyclin that activates the IP receptor on vascular smooth‑muscle cells. This activation raises cyclic AMP levels, causing vasodilation, inhibition of platelet aggregation, and antiproliferative effects on the pulmonary arterial wall, which together improve circulation and reduce vascular resistance.

The dosage of Iloprost Waymade is individualized and set by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare professionals determine the infusion rate, duration, and total daily dose according to approved guidelines and patient monitoring.

Safety data for Iloprost in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate each case carefully and discuss possible risks with the patient.

To place an order, submit an enquiry on the Iloprost Waymade product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Iloprost shares the same prostacyclin receptor agonist mechanism as other agents like epoprostenol and treprostinil, but it is administered intravenously and has a shorter half‑life, allowing more precise dose titration. Its side‑effect profile is similar, though individual tolerability may differ among patients.

Iloprost Waymade should be stored refrigerated between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution, as these actions can compromise product stability.

Iloprost Waymade is given as an intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescriber, and patients are monitored for blood pressure, heart rate, and any adverse reactions throughout the administration.

Serious risks include severe hypotension, pulmonary edema, significant bleeding, thrombocytopenia, cardiac arrhythmias, and rare anaphylactic reactions. Prompt recognition and medical management of these events are essential, and patients should be closely monitored during and after infusion.

Iloprost Waymade is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, those with severe uncontrolled hypotension, active bleeding disorders, or severe hepatic impairment. Clinicians should also exercise caution in patients with recent myocardial infarction or unstable cardiac conditions.